We provide you with 20 years of free, institutional-grade data for PHVS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PHVS. Explore the full financial landscape of PHVS stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about PHVS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Pharvaris B.V(NASDAQ:PHVS) 
Pharvaris is a clinical-stage company focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
Website: http://www.pharvaris.com
Founded: 2015
CEO: Berndt Modig
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends